Clinical Trials Browser

Brain Neoplasms, Carcinoma, Ependymoma, Histiocytosis, Langerhans-Cell, Medulloblastoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT00716066 2026-02-27

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Phase 2 Active not recruiting

53 enrolled

CNS

Rasmussen subacute encephalitis, Autoimmune Diseases, Myasthenia Gravis, Neuromyelitis Optica, Lambert-Eaton Myasthenic Syndrome, Stiff-Person Syndrome, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Vasculitis, Central Nervous System, Opsoclonus-Myoclonus Syndrome

NCT04469530 2026-02-27

AflacST1903

Phase 2 Recruiting

55 enrolled

Other solid neoplasm

Solid Tumor

NCT01356290 2026-02-23

MEMMAT

Phase 2 Recruiting

232 enrolled

CNS

Ependymoma, Medulloblastoma, Recurrence

NCT01946529 2026-02-23

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Phase 2 Active not recruiting

24 enrolled 11 charts

Neuroectodermal Tumors, Primitive, Peripheral, Desmoplastic Small Round Cell Tumor

NCT06830694 2026-02-23

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

Phase 2 Recruiting

50 enrolled

Thoracic

Small Cell Lung Carcinoma

Clinical Trials

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

P+R-ICE

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

PEERS

Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

MOZART

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Aurora004

Aurora 005

Therapy for Children With Advanced Stage Neuroblastoma

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer

TICE

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

SJATRT

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

AflacST1502

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

AflacST1903

MEMMAT

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment